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John Myburgh1,2*, Simon Finfer1,3 and Rinaldo Bellomo1,4Meybohm and colleagues [1] propose that hydroxyethyl
starch (HES) may be used safely in hypovolemic patients
by applying a clinical algorithm and by restricting the
dose administered.
The authors question the validity of the results of the
two trials that constitute over 60% of current data [2,3]
and misleadingly state that in the Crystalloid vs.
Hydroxyethyl Starch Trial (CHEST), HES administration
did not increase the use of renal replacement therapy by
referring to the adjusted analyses that were published in
the electronic supplement [2]. The unadjusted analysis
was pre-specified as the principal outcome measure and
is the appropriate measure to influence clinical practice.
The authors also ignore the consistent signal of harm
associated with HES, specifically increased mortality and
use of renal replacement therapy that is evident despite
wide variations in aggregate doses of HES in the three
major clinical trials: 70 ml/kg in the Efficacy of Volume
Substitution and Insulin Therapy in Severe Sepsis trial
[4], 44 ml/kg in the Scandinavian Starch for Severe
Sepsis/Septic Shock study [3], and 5 ml/kg in CHEST.
Meybohm and colleagues make no comment that adverse
effects of HES represent an overall toxic effect caused by
increased tissue accumulation that is recognised as a
dose-dependent, generic HES effect [5].
The ‘presumably correct indication’ and the algorithm
they propose have not been validated nor are they sup-
ported by any credible clinical evidence. Their proposed
algorithm and target population must be evaluated in
rigorously conducted randomized controlled trials before
being considered for adoption into clinical practice.
Given the consistent evidence that HES is nephrotoxic
and may increase mortality [6], it is doubtful that institu-
tional ethics committees would approve such a trial, or
that informed patients would consent to participate.* Correspondence: jmyburgh@georgeinstitute.org.au
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